Weight-based dosing vs fixed dosing of pembrolizumab: An economic analysis

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Original language	English
Pages (from-to)	549-551
Number of pages	3
Journal	Clinical Advances in Hematology and Oncology
Volume	16
Issue number	8
State	Published - Aug 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{304de64e688f4092af4c1a834e8c972d,

title = "Weight-based dosing vs fixed dosing of pembrolizumab: An economic analysis",

author = "Daniel Goldstein",

year = "2018",

month = aug,

language = "אנגלית",

volume = "16",

pages = "549--551",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "8",

}

TY - JOUR

T1 - Weight-based dosing vs fixed dosing of pembrolizumab

T2 - An economic analysis

AU - Goldstein, Daniel

PY - 2018/8

Y1 - 2018/8

UR - http://www.scopus.com/inward/record.url?scp=85059067062&partnerID=8YFLogxK

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 30148826

AN - SCOPUS:85059067062

SN - 1543-0790

VL - 16

SP - 549

EP - 551

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 8

ER -